ARGLU1

Across TCGA pan-cancer cohorts, ARGLU1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARGLU1 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ARGLU1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARGLU1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

HNSC, PDAC, and LUAD are the cancer types where ARGLU1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.676	0.861	.019	18	view →
PDAC	DFS	Median	IV	0.785	0.214	.006	10	view →
LUAD	OS	Tertile	II,III,IV	0.879	0.323	.014	9	view →
UCEC	DFS	Median	All	1.000	0.938	.026	4	view →
GBM	OS	Tertile	All	0.614	0.282	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARGLU1–HNSC (DFS)

Open the HNSC breakdown →